Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy
- PMID: 404309
- DOI: 10.1210/jcem-44-5-892
Response to thyrotropin releasing hormone: an objective criterion for the adequacy of thyrotropin suppression therapy
Abstract
Most serum thyrotropin (TSH) assays do not adequately discriminate between normal values and absent TSH. We therefore evaluated the TSH response to thyrotropin releasing hormone (TRH) as a criterion for the adequacy of TSH suppression therapy. Twenty-six outpatients with various thyroid disorders (cancer, 10; nodules, 9; miscellaneous, 4; hypothyroidism after 131I therapy for Graves' disease, 3) were studied. Using the frequent sampling technique (samples every 20 min) in two normal volunteers and one untreated patient who was TRH-responsive, we first confirmed the observation that TSH secretion occurred episodically throughout the 24-h period. In contrast, serum TSH was undetectable (less than 0.6 micronU/ml) throughout the 24-h period in 5 patients on TSH suppression therapy who were TRH-unresponsive and one who had a minimal response to TRH. Thus, TRH-unresponsive patients did not secrete measurable amounts of TSH throughout the 24-h period. To suppress TSH secretion, all patients were treated with L-thyroxine (T4) at doses which resulted in undetectable TSH values in random plasma samples. TRH tests were carried out only when random TSH concentrations were less than 0.6 micronU/ml. Seven of the twenty-six patients (27%) including two with thyroid cancer were TRH-responsive indicating a potential for TSH secretion. In these seven, the T4 dose was adjusted until they were TRH-unresponsive. The mean change in T4 dose of these 7 patients was 20+/-10 (SD) microng/day and this resulted in a mean increase of 1.5+/-1.1 microng/dl for T4 and 20+/-20 ng/dl for T3. For all patients, the mean T4 dose required for TSH suppression was 172+/-53 microng/day or 2.6+/-0.8 microng per day per kg body weight. Twenty-three of 26 patients required between 100-200 microng/day and the remaining 3, 250-300 microng/day. The T4 dose required to suppress TSH resulted in normal serum concentrations of T4. 9.1+/-2.0 MICRONG/DL, AND T3, 136.7+/-33.6 NG/DL. These T4 doses did not produce a rapid heart rate, either awake or asleep, arrhythmias, or electrocardiographic abnormalties as assessed by 24-h Holter monitor tracings in 11 patients. Our results thus show that the T4 dose which results in an unresponsive TRH test ensures that serum TSH will remain undetectable (less than 0.6 micronU/ml) throughout the 24-h period. An unresponsive TRH test, therefore, appears to be a very useful and reliable index of TSH suppression.
Similar articles
-
Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.J Clin Endocrinol Metab. 1987 Dec;65(6):1265-71. doi: 10.1210/jcem-65-6-1265. J Clin Endocrinol Metab. 1987. PMID: 3680483
-
The comparative effect of T4 and T3 on the TSH response to TRH in young adult men.J Clin Endocrinol Metab. 1977 Feb;44(2):273-8. doi: 10.1210/jcem-44-2-273. J Clin Endocrinol Metab. 1977. PMID: 402379
-
Serum thyrotropin response to thyrotropin-releasing hormone and free thyroid hormone indices in patients with familiar thyroxine-binding globulin deficiency.Endocrinol Jpn. 1976 Aug;23(4):313-7. Endocrinol Jpn. 1976. PMID: 828576
-
Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.Thyroid. 2010 Feb;20(2):135-46. doi: 10.1089/thy.2009.0311. Thyroid. 2010. PMID: 20151821 Review.
-
Clinical utility and cost-effectiveness of sensitive thyrotropin assays in ambulatory and hospitalized patients.Mayo Clin Proc. 1988 Dec;63(12):1214-22. doi: 10.1016/s0025-6196(12)65408-1. Mayo Clin Proc. 1988. PMID: 3143866 Review.
Cited by
-
Variable thyrotropin response to thyrotropin-releasing hormone after small decreases in plasma free thyroid hormone concentrations in patients with nonthyroidal diseases.J Clin Invest. 1980 Sep;66(3):451-6. doi: 10.1172/JCI109875. J Clin Invest. 1980. PMID: 6772675 Free PMC article.
-
Different rates of thyrotropin suppression after total body scan in patients with thyroid cancer: effect of an optimal saturation regimen with thyroxine or triiodothyronine.J Endocrinol Invest. 1983 Dec;6(6):455-61. doi: 10.1007/BF03348345. J Endocrinol Invest. 1983. PMID: 6423722
-
Twenty-four hour variations of triiodothyronine (T3) levels in patients who had thyroid ablation for thyroid cancer, receiving T3 as suppressive treatment.J Endocrinol Invest. 1980 Oct-Dec;3(4):353-6. doi: 10.1007/BF03349370. J Endocrinol Invest. 1980. PMID: 6782151
-
Nodular goiter: effects of surgery and thyroxine medication.World J Surg. 1986 Jun;10(3):481-7. doi: 10.1007/BF01655315. World J Surg. 1986. PMID: 3088852 No abstract available.
-
Methods of investigation in the diagnosis and management of thyroid carcinoma.World J Surg. 1981 Jan;5(1):49-59. doi: 10.1007/BF01657834. World J Surg. 1981. PMID: 7233955 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources